Valine

Valine

SCHEMBL754999

CC(C)[C@H](N)C(=O)O.Oc1ccccc1

nearest known ligand 0.62

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 2/20 0.62
LMNA P02545 2/20 0.47
HIF1A Q16665 1/20 0.47
KDM4E B2RXH2 1/20 0.47
TDP1 Q9NUW8 2/20 0.46
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
GLA P06280 1/20 0.46
CA3 P07451 1/20 0.46
CA4 P22748 1/20 0.46
CA9 Q16790 1/20 0.46
CA14 Q9ULX7 1/20 0.46
SLC1A2 P43004 4/20 0.44
SLC1A3 P43003 3/20 0.44
SLC1A1 P43005 3/20 0.44
MEN1 O00255 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Valine SCHEMBL5479272 1.00 SLC7A5 (0.62) SLC7A5LMNAHIF1AKDM4ETDP1
Valine SCHEMBL1424875 0.91 SLC7A5 (0.68) SLC7A5LMNAHIF1AKDM4ETDP1
Biphenyl SCHEMBL2494151 0.85 SLC7A5 (0.65) SLC7A5SLC1A2SLC1A3SLC1A1CYP1A2
Biphenyl SCHEMBL27824248 0.85 SLC7A5 (0.65) SLC7A5SLC1A2SLC1A3SLC1A1CYP1A2
Phenol SCHEMBL2786799 0.85 CA12 (0.52) SLC7A5LMNAHIF1AKDM4ETDP1
Phenol SCHEMBL2786796 0.85 CA12 (0.52) SLC7A5LMNAHIF1AKDM4ETDP1
Valine SCHEMBL4582565 0.84 SLC7A5 (0.88) SLC7A5LMNATDP1SLC1A2SLC1A3
Valine SCHEMBL28052598 0.84 SLC7A5 (0.88) SLC7A5LMNATDP1SLC1A2SLC1A3
Valine SCHEMBL5324319 0.84 SLC7A5 (0.58) SLC7A5LMNAHIF1ATDP1CA3
Valine SCHEMBL6639200 0.83 SLC7A5 (0.62) SLC7A5SLC1A2SLC1A3SLC1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1177812-C Process for preparing O-phenoxyalkylhydroxylamine or O-phenoxyalkyloxime isomer mixtures �����ɷ� 2004-12-01 CN claimed
CN-1381522-A Stable middle voltoge and high voltage cable insulation composition CIBA SC HOLDING AG (CH) 2002-11-27 CN claimed
EP-0788475-B1 PROCESS FOR PRODUCING ISOMER MIXTURES FROM O-PHENOXYALKYLHYDROXYL AMINES OR O-PHENOXYALKYLOXIMES BASF AG (DE) 1999-10-20 EP claimed
US-5739402-A Process for the preparation of mixtures of isomers of O-phenoxy-alkylhydroxylamines or O-phenoxyalkyloximes BASF AKTIENGESELLSCHAFT (DE) 1998-04-14 US claimed
EP-0788475-A1 PROCESS FOR PRODUCING ISOMER MIXTURES FROM O-PHENOXYALKYLHYDROXYL AMINES OR O-PHENOXYALKYLOXIMES BASF AKTIENGESELLSCHAFT (DE) 1997-08-13 EP claimed
CN-1150418-A Process for producing isomer mixtures from 0-phenoxyalkylhydroxyl amines or 0-phenoxyalkyloximes BASF AG (DE) 1997-05-21 CN claimed
WO-1995030648-A1 PROCESS FOR PRODUCING ISOMER MIXTURES FROM O-PHENOXYALKYLHYDROXYL AMINES OR O-PHENOXYALKYLOXIMES BASF AKTIENGESELLSCHAFT (DE) 1995-11-16 WO claimed
CN-118221656-A Compounds useful for the treatment of gastrointestinal disorders 阿德利克斯股份有限公司 2024-06-21 CN disclosed
CN-117871734-A Characterization method of lignin in environmental sample 西北农林科技大学 2024-04-12 CN disclosed
CN-110267944-B Compounds useful for the treatment of gastrointestinal disorders 阿德利克斯股份有限公司 2024-03-08 CN disclosed
US-11242337-B2 Compounds useful for treating gastrointestinal tract disorders ARDELYX, INC. (US) 2022-02-08 US disclosed
US-11130740-B2 Substituted 2,3-dihydro-1H-indene analogs and methods using same ARBUTUS BIOPHARMA CORPORATION (CA) 2021-09-28 US disclosed
WO-2020255021-A1 COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND SMALL MOLECULE PDL1 OR PD1 INHIBITOR Janssen Sciences Ireland Unlimited Company (IE) 2020-12-24 WO disclosed
EP-0099177-A1 Halogenophenyl glyceride esters IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1984-01-25 EP disclosed
US-4410675-A EPOXY RESINS, ALDEHYDE, MERCAPTOCARBOXYLIC ACID OR SULFUROUS ACID, PROTECTIVE COATINGS CIBA-GEIGY CORPORATION (US) 1983-10-18 US disclosed
US-4374258-A PHOTOSTABILITY; HEAT AND OXIDATION RESISTANCE; ADDITION POLYMERS BASF AKTIENGESELLSCHAFT (DE) 1983-02-15 US disclosed
US-4362853-A MANNICH REACTION OF BISPHENOL EPOXY RESIN WITH ALDEHYDE AND AMINO ACID CIBA-GEIGY CORPORATION (US) 1982-12-07 US disclosed
EP-0065668-A2 Urea derivatives, their preparation and use CELAMERCK GmbH & Co. KG (DE) 1982-12-01 EP disclosed
EP-0051561-A1 Resinlike salts, their preparation and their use in coatings CIBA-GEIGY AG (CH) 1982-05-12 EP disclosed
US-4005150-A Phenyl ethers having juvenile hormone activity CESKOSLOVENSKA AKADEMIE VED (CS) 1977-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11242337-B2 Compounds useful for treating gastrointestinal tract disorders SLC10A2, FABP2, SLC10A1 SLC7A5 518/4885LMNA 4122/4885HIF1A 3759/4885
US-11130740-B2 Substituted 2,3-dihydro-1H-indene analogs and methods using same HAVCR2, DHPS, IDH3A SLC7A5 3029/4885LMNA 1324/4885HIF1A 901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.